U.S. stock market update: Incannex Healthcare up 9.37%

U.S. Stock Market Midday Update Incannex Healthcare rose 9.37%, with increased trading volume. Based on recent important news: On August 22, Incannex Healthcare announced that the board approved a stock repurchase plan of up to $20 million, driving the stock price up by 36.9%. On August 23, the short interest in Incannex Healthcare rose to 82.61%, indicating an increased bearish sentiment in the market regarding its stock. On August 22, the company stated that the repurchase plan would be executed through open market purchases, further enhancing shareholder value. Stocks with High Trading Volume in the Industry Eli Lilly fell 0.80%, with increased trading volume. Based on recent important news: On August 25, Eli Lilly reached a clinical supply agreement with Immuneering to evaluate the effects of Atebimetinib in combination with Olomorafib, causing stock price fluctuations. On August 23, research indicated that Eli Lilly's Mounjaro drug could reduce cancer risk, leading to a positive market reaction. On August 22, poor trial data for Eli Lilly's obesity drug put pressure on the stock price. Novo Nordisk rose 1.80%, with increased trading volume. Based on recent important news: On August 25, Novo Nordisk approved the new MASH indication application for semaglutide, promoting industry development and driving the stock price up. On August 23, research showed that GLP-1 drugs reduce cancer risk, boosting market confidence and increasing stock prices. On August 22, Novo Nordisk invested in an expansion project in Tianjin, demonstrating its focus on the Chinese market and enhancing investor confidence. Johnson & Johnson fell 0.37%, with increased trading volume. Based on recent important news: On August 22, Johnson & Johnson announced a $2 billion investment in North Carolina to expand manufacturing capacity in response to potential drug import tariff policies, causing the stock price to decline. On August 22, Citigroup raised Johnson & Johnson's target stock price to $200, leading to a positive market reaction. On August 22, Johnson & Johnson's new indication application for niraparib and abiraterone was accepted, with the market holding an optimistic view on its prospects. Stocks with High Market Capitalization in the Industry AstraZeneca fell 0.59%, with increased trading volume. Based on recent important news: On August 22, AstraZeneca announced that its durvalumab was approved domestically for the treatment of certain types of breast cancer, which could boost market confidence but failed to offset overall market pressure. On August 22, AstraZeneca's acquisition of the Chinese business for rosuvastatin received unconditional approval, indicating the company's expansion strategy in the Chinese market. On August 22, AstraZeneca established a research and development center in the Philippines, demonstrating its long-term investment plans in the Asian market